Seminars in Hematology
Volume 40, Issue 1 , Pages 4-12 , January 2003

Prognosis and prognostic factors for patients with chronic myeloid leukemia: Nontransplant therapy

References 

  1. Altman DG, Lausen B, Sauerbrei W, et al.  Dangers of using “optimal” cutpoints in the evaluation of prognostic factors. J Natl Cancer Inst. 1994;86:829–835
  2. Bonifazi F, De Vivo A, Rosti G, et al.  Testing Sokal's and the new prognostic score for chronic myeloid leukaemia treated with α-interferon. Br J Haematol. 2000;111:587–595
  3. Bonifazi F, De Vivo A, Rosti G, et al.  Chronic myeloid leukemia and interferon-alpha: A study of complete cytogenetic responders. Blood. 2001;98:3074–3081
  4. Gratwohl A, Hermans J, Goldman JM, et al.  Risk assessment for patients with chronic myeloid leukemia before allogeneic blood or marrow transplantation. Lancet. 1998;352:1087–1092
  5. Guilhot F, Chastang C, Michallet M, et al.  Interferon alfa-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia. French Chronic Myeloid Leukemia Study Group. N Engl J Med. 1997;337:223–229
  6. Hasford J, Ansari H, Pfirrmann M, et al.  Analysis and validation of prognostic factors for CML. Bone Marrow Transplant. 1996;17(suppl 3):S49–S54
  7. Hasford J, Pfirrmann M, Hehlmann R, et al.  A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. J Natl Cancer Inst. 1998;90:850–858
  8. Hasford J, Pfirrmann M, Hehlmann R, et al.  Prognostic factors. In:  Carella A,  Daley G,  Eaves C, et al. editor. Chronic Myeloid Leukemia—Biology and Treatment. London, UK: Martin Dunitz; 2001;p. 205–223
  9. Hehlmann R, Heimpel H, Hasford J, et al.  Randomized comparison of interferon-alpha with busulfan and hydroxyurea in chronic myelogenous leukemia. The German CML Study Group. Blood. 1994;84:4064–4077
  10. Hehlmann R, Heimpel H, Hossfeld DK, et al.  Randomized study of the combination of hydroxyurea and interferon alpha versus hydroxyurea monotherapy during the chronic phase of chronic myelogenous leukemia (CML Study II). The German Study Group. Bone Marrow Transplant. 1996;17(suppl 3):S21–S24
  11. Kantarjian H, Sawyers C, Hochhaus A, et al.  Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med. 2002;346:645–652
  12. Mahon FX, Fabéres C, Pueyo S, et al.  Response at three months is a good predictive factor for newly diagnosed chronic myeloid leukemia patients. Blood. 1998;92:4059–4065
  13. Minot GR, Buckman TE, Isaacs R. Chronic myelogenous leukemia. J Am Med Assoc. 1924;82:1489–1494
  14. Ohnishi K, Ohno R, Tomonaga M, et al.  A randomized trial comparing interferon-alpha with busulfan for newly diagnosed chronic myelogenous leukemia in chronic phase. Blood. 1995;86:906–916
  15. Ozer H, George SL, Schiffer CA, et al.  Prolonged subcutaneous administration of recombinant alpha 2b interferon in patients with previously untreated Philadelphia chromosome-positive chronic-phase chronic myelogenous leukemia. Effect on remission duration and survival: Cancer and Leukemia Group B Study 8593. Blood. 1993;82:2975–2984
  16. Pfirrmann M, Hasford J. Testing Sokal's and the new prognostic score for chronic myeloid leukaemia treated with α-interferon: Comments. Br J Haematol. 2001;114:241–242 (letter)
  17. Savage DG, Antman KH. Imatinib mesylate—A new oral targeted therapy. N Engl J Med. 2002;346:683–693
  18. Sokal JE, Cox EB, Baccarani M, et al.  Prognostic discrimination in “good-risk” chronic granulocytic leukemia. Blood. 1984;63:789–799
  19. Steegmann JL, Odriozola J, Rodriguez-Salvans F, et al.  Stage, percentage of basophils at diagnosis, hematologic response within six months, cytogenetic response in the first year: the main prognostic variables affecting outcome in patients with chronic myeloid leukemia in chronic phase treated with interferon-alpha. Results of the CML89 trial of the Spanish Collaborative Group on interferon-alpha-2a and CML. Haematologica. 1999;84:978–987
  20. Talpaz M, Kantarjian HM, McCredie KB, et al.  Clinical investigation of human alpha interferon in chronic myelogenous leukemia. Blood. 1987;69:1280–1288
  21. Thaler J, Gastl G, Fluckinger T, et al.  Treatment of chronic myelogenous leukemia with interferon alfa-2c: Response rate and toxicity in a phase II multicenter study. The Austrian Biological Response Modifier (BRM) Study Group. Semin Hematol. 1993;30(suppl 3):S17–S19
  22. Thaler J, Hilbe W. Comparative analysis of two consecutive phase II studies with IFN-alpha and IFN-alpha + ara-C in untreated chronic-phase CML patients. Austrian CML Study Group. Bone Marrow Transplant. 1996;17(suppl 3):S25–S28
  23. The Benelux CML Study Group: Randomized study on hydroxyurea alone versus hydroxyurea combined with low-dose interferon-alfa-2b for chronic myeloid leukemia. Blood. 1998;91:2272–2713
  24. The Italian Cooperative Study Group on Chronic Myeloid Leukemia . Interferon alfa-2a as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia. N Engl J Med. 1994;330:820–825
  25. Thomas MJ, Irving JEA, Lennard AL, et al.  Validation of the Hasford score in a demographic study in chronic granulocytic leukemia. J Clin Pathol. 2001;54:491–493

☆ Address reprint requests to Professor Dr Joerg Hasford, Forschungsgruppe CML, Institut für Medizinische Informationsverarbeitung, Biometrie und Epidemiologie (IBE), Universität München, Marchioninistr. 15, 81377 München, Germany.

PII: S0037-1963(03)70038-9

Seminars in Hematology
Volume 40, Issue 1 , Pages 4-12 , January 2003

Article Tools

* Image Usage & Resolution